CR11469A - Aminotiazoles y sus usos - Google Patents

Aminotiazoles y sus usos

Info

Publication number
CR11469A
CR11469A CR11469A CR11469A CR11469A CR 11469 A CR11469 A CR 11469A CR 11469 A CR11469 A CR 11469A CR 11469 A CR11469 A CR 11469A CR 11469 A CR11469 A CR 11469A
Authority
CR
Costa Rica
Prior art keywords
aminotiazoles
atropisomers
rotamers
racemates
tautomers
Prior art date
Application number
CR11469A
Other languages
English (en)
Inventor
Simon Bushell
Mathew J Lamarche
Jennifer Leeds
Lewis Whitehead
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40377437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11469(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR11469A publication Critical patent/CR11469A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente solicitud describe compuestos organicos que son utiles para el tratamiento, la prevencion y/o la mejora de enfermedades, en particular infecciones bacterianas, formula (I), y sales farmaceuticamente aceptables, enantiomeros, estereoisomeros, rotameros, tautomeros, diaestereomeros, atropisomeros o racematos de los mismos, incluyendo su N-oxido de piridina.
CR11469A 2007-12-12 2010-06-01 Aminotiazoles y sus usos CR11469A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1312207P 2007-12-12 2007-12-12
US2470908P 2008-01-30 2008-01-30

Publications (1)

Publication Number Publication Date
CR11469A true CR11469A (es) 2010-07-09

Family

ID=40377437

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11469A CR11469A (es) 2007-12-12 2010-06-01 Aminotiazoles y sus usos

Country Status (26)

Country Link
US (4) US8426356B2 (es)
EP (1) EP2229386B1 (es)
JP (2) JP5286366B2 (es)
KR (2) KR20120047335A (es)
CN (1) CN101945866B (es)
AR (1) AR069628A1 (es)
AU (1) AU2008334659A1 (es)
BR (1) BRPI0821138A2 (es)
CA (1) CA2708793C (es)
CL (1) CL2008003688A1 (es)
CO (1) CO6290661A2 (es)
CR (1) CR11469A (es)
CU (1) CU20100119A7 (es)
EA (2) EA201400280A1 (es)
EC (1) ECSP10010244A (es)
ES (1) ES2542878T3 (es)
GT (1) GT201000166A (es)
HN (1) HN2010001176A (es)
IL (1) IL206104A (es)
MA (1) MA31869B1 (es)
MY (1) MY156466A (es)
NZ (1) NZ585788A (es)
PE (1) PE20091108A1 (es)
TN (1) TN2010000254A1 (es)
TW (1) TWI430804B (es)
WO (1) WO2009074605A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060977A1 (es) * 2006-05-31 2008-07-23 Novartis Ag Aminotiazoles y sus usos
EP2229386B1 (en) * 2007-12-12 2015-06-03 Novartis AG An aminothiazole derivative as antibacterial agent
WO2016081825A1 (en) 2014-11-21 2016-05-26 KamTek, Inc. Methods and compositions for treating clostridium difficile associated disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202241A (en) 1988-09-09 1993-04-13 Gruppo Lepetit S.P.A. Antibiotic GE 2270
DE69016284T2 (de) 1989-07-04 1995-05-24 Lepetit Spa Antibiotikum GE 22270, Faktoren A1,A2,A3 und H.
ES2071143T3 (es) 1990-03-08 1995-06-16 Lepetit Spa Factores b1, b2, c1, c2, d1, d2, e y t del antibiotico ge 2270.
IL100572A (en) 1991-01-03 1997-01-10 Lepetit Spa Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them
DK0529410T3 (da) 1991-08-30 1998-05-11 Biosearch Italia Spa Antibiotikum GE 2270 faktor C2a
US5882900A (en) 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
KR960703410A (ko) 1992-12-22 1996-08-17 프란세스코 마체타 항생물질 GE 37468 A, B 및 C(Antibiotics GE 37468 A, B and C)
JPH10508476A (ja) 1994-11-08 1998-08-25 グルポ・レペチツト・エス・ピー・エイ 抗生物質ｇｅ２２７０因子ｄ▲下２▼を得るための微生物変換法
WO1996024608A1 (en) 1995-02-07 1996-08-15 Biosearch Italia S.P.A. Basic oxazoline-amide derivatives of ge 2270 and ge 2270-like antibiotics
DE69600244T2 (de) 1995-02-07 1998-10-01 Biosearch Italia Spa Basische prolinamid derivate von ge2270 und ge2270-ahnlichten antibiotika
ES2186866T3 (es) 1996-02-14 2003-05-16 Biosearch Italia Spa Derivados de factores del antibiotico ge2270.
JPH1059997A (ja) 1996-08-22 1998-03-03 Microbial Chem Res Found アミチアマイシンアミド誘導体
KR20050026401A (ko) 2002-06-17 2005-03-15 비큐론 파마세티컬스 인코포레이티드 여드름 치료를 위한 ｇｅ 2270 인자 ａ3의 아미드유도체의 용도
CA2580882A1 (en) 2004-09-22 2006-08-17 Merck & Co., Inc. Antibiotic compound
CN101400684B (zh) * 2005-07-13 2011-06-15 大正制药株式会社 噻唑类化合物
AR060977A1 (es) 2006-05-31 2008-07-23 Novartis Ag Aminotiazoles y sus usos
BRPI0720542A2 (pt) 2006-12-20 2014-01-21 Novartis Ag Compostos antibacterianos e processos para a sua produção
CN101772506B (zh) 2007-06-04 2014-02-12 诺华股份有限公司 大环化合物及其用途
EP2229386B1 (en) * 2007-12-12 2015-06-03 Novartis AG An aminothiazole derivative as antibacterial agent

Also Published As

Publication number Publication date
US20140274878A1 (en) 2014-09-18
CO6290661A2 (es) 2011-06-20
CA2708793A1 (en) 2009-06-18
EP2229386B1 (en) 2015-06-03
GT201000166A (es) 2012-04-30
CL2008003688A1 (es) 2009-06-19
US20170015704A1 (en) 2017-01-19
CN101945866A (zh) 2011-01-12
EA020205B1 (ru) 2014-09-30
US20090156628A1 (en) 2009-06-18
MA31869B1 (fr) 2010-11-01
TW200932256A (en) 2009-08-01
IL206104A0 (en) 2010-11-30
EP2229386A1 (en) 2010-09-22
JP2013189468A (ja) 2013-09-26
CA2708793C (en) 2016-06-21
TWI430804B (zh) 2014-03-21
MY156466A (en) 2016-02-26
PE20091108A1 (es) 2009-08-24
WO2009074605A1 (en) 2009-06-18
US20130231275A1 (en) 2013-09-05
NZ585788A (en) 2011-07-29
CU20100119A7 (es) 2011-10-14
AR069628A1 (es) 2010-02-03
JP5286366B2 (ja) 2013-09-11
ES2542878T3 (es) 2015-08-12
KR20100090809A (ko) 2010-08-17
EA201400280A1 (ru) 2014-08-29
KR101187111B1 (ko) 2012-09-28
KR20120047335A (ko) 2012-05-11
US8426356B2 (en) 2013-04-23
IL206104A (en) 2015-03-31
AU2008334659A1 (en) 2009-06-18
ECSP10010244A (es) 2010-07-30
JP2011506394A (ja) 2011-03-03
BRPI0821138A2 (pt) 2015-06-16
US9492496B2 (en) 2016-11-15
HN2010001176A (es) 2012-12-10
CN101945866B (zh) 2013-06-19
TN2010000254A1 (en) 2011-11-11
EA201000890A1 (ru) 2011-02-28
CU23908B1 (es) 2013-06-28

Similar Documents

Publication Publication Date Title
NI201200016A (es) Derivados de piridina y pirazina como moduladores de cinasa de proteína
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
ECSP099451A (es) Compuestos de urea policíclicos antibacterianos
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
ECSP13012400A (es) Pirazolo[1,5-a]pirimidinas como agentes antivirales
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
UY32123A (es) Derivados de n - (sustituido) - 4 - (but-2-iniloxi) - benzamida, sus racematos, diastereòmeros, enantiòmeros y las sales de los mismos y aplicaciones
UY31984A (es) DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
CR8744A (es) Compuestos terapeuticos
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY30835A1 (es) 8-alquinilxantinas y derivados
UY31141A1 (es) Compuestos de piperidina y sus usos
ECSP10010659A (es) Derivados heterocíclicos de la urea y sus métodos de empleo
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
ECSP088922A (es) Derivados de amino-tiazol y sus usos como agentes antibacterianos
CO6361995A2 (es) Derivados de isoquinolinona como antagonistas de nk3
ECSP099506A (es) Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
CR11469A (es) Aminotiazoles y sus usos
GT201100039A (es) Agentes antifúngicos
UY31805A (es) Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor